Get the Stockscreener App
0.91
4.21%
-0.04
Aprea Therapeutics Inc stock is traded at $0.91, with a volume of 109.71K.
It is down -4.21% in the last 24 hours and down -2.14% over the past month.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
See More
Previous Close:
$0.95
Open:
$0.96
24h Volume:
109.71K
Relative Volume:
0.31
Market Cap:
$11.27M
Revenue:
$285.80K
Net Income/Loss:
$-12.60M
P/E Ratio:
-0.4609
EPS:
-1.9743
Net Cash Flow:
$-13.44M
1W Performance:
+13.75%
1M Performance:
-2.14%
6M Performance:
-27.20%
1Y Performance:
-45.51%
1-Day Range:
$0.90
$0.97
1-Week Range:
$0.787
$0.97
52-Week Range:
$0.548
$2.11
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.91 | 11.76M | 285.80K | -12.60M | -13.44M | -1.9743 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know - MSN
Aprea Expands Cancer Trial After $30 Million Financing - MyChesCo
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know - sharewise.com
This Aprea Therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
Aprea Therapeuticsfiles for resale of up to 5.5 million shares by selling stockholdersSEC filing - marketscreener.com
[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7) - Stock Titan
Aprea Therapeutics 1Q Research and Development Expenses $1.6M >APRE - Moomoo
Wedbush Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target - TipRanks
Press Release: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Moomoo
Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating - Moomoo
Aprea Therapeutics, Inc. Q1 2026 10-Q Report – Financials, Risk Factors, and Forward-Looking Statements - Minichart
Aprea Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Aprea Therapeutics Highlights Q1 2026 Results and Clinical Progress - TipRanks
Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher - ChartMill
Aprea Therapeutics (NASDAQ: APRE) trims Q1 loss and raises over $34M to extend cash runway - Stock Titan
APREA THERAPEUTICS ($APRE) Releases Q1 2026 Earnings - Quiver Quantitative
Aprea Therapeutics, Inc. 1Q 2026: Revenue $0 EPS $(0.22) — 10-Q Summary - TradingView
Aprea Therapeutics Reports Q1 2026 Results: $30M Financing Boosts APR-1051 Clinical Progress and Extends Cash Runway to 2028 - Minichart
Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Aprea Therapeutics Closes Oversubscribed $30 Million Private Placement to Advance APR-1051 Development and Reports Positive Early Data from Phase 1 Trial - Quiver Quantitative
Aprea Therapeutics Q1 net loss narrows as R&D expenses fall - TradingView
8-K: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Updatemoomoo - Moomoo
Aprea (NASDAQ: APRE) extends cash runway and reports Q1 2026 results - Stock Titan
Early tumor responses and $30M cash boost for Aprea cancer drug - Stock Titan
A Breakout Year for WEE1? Oppenheimer Sees 6x Upside in This Under-the-Radar Biotech - Barchart.com
TradingKey - TradingKey
APRE (Aprea) beats Q4 earnings by 20%, but shares fall 2.3% amid growth concerns.Social Momentum Signals - Newser
APRE (Aprea) Q4 earnings beat expectations with smaller loss than estimated, shares climb 5.66%.Put/Call Ratio - Newser
Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Oppenheimer Initiates Aprea Therapeutics at Outperform With $5 Price Target - marketscreener.com
Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential - Investing.com Nigeria
Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential By Investing.com - Investing.com South Africa
APRE | Aprea Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative
APRE Stock Price, Quote & Chart | APREA THERAPEUTICS INC (NASDAQ:APRE) - ChartMill
APRE SEC FilingsAprea Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Reverse split and director votes in Aprea Therapeutics (NASDAQ: APRE) 2026 proxy - Stock Titan
[EFFECT] Aprea Therapeutics, Inc. SEC Filing - Stock Titan
74.35M shares registered for resale by Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
CatalYm picks ex-Aprea CEO Christian Schade to chair board - Stock Titan
Aprea Abstract Accepted for ASCO on APR-1051 Phase 1 Study - MyChesCo
Aprea Therapeutics (NASDAQ: APRE) reporting group discloses 9.9% stake - Stock Titan
Two life sciences companies with Doylestown connections raise $119M - MSN
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):